Published in Drug Week, June 22nd, 2007
Advanced Viral Research Corporation is developing a new class of cytoprotective drug which may be useful in the treatment of cachexia (body wasting), appetite loss, and lethargy in patients with cancer and HIV-AIDS. The compound also is being evaluated in a Phase II topical wound healing study after demonstrating accelerated wound healing properties in a well...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.